TOPLINE:

Investigators reported that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with significant improvements in clinical severity, patient-reported outcomes, and weight in patients with hidradenitis suppurativa (HS) and obesity.

METHODOLOGY:

The retrospective multicenter cohort study evaluated 66 adults (median age, 46 years; 58% women) with HS who received semaglutide, dulaglutide, or liraglutide for at least 3 months, using data from eight French hospitals, between 2017 and 2024.

Their median BMI was 39.4, and 86% of patients had diabetes; 45%, 32%, and 23% of patients had Hurley stages I, II, and III disease, respectively.

Outcomes included HS-Physician’s Global Assessment (HS-PGA), flare frequency, Numerical Rating Scale (NRS)-Pain, NRS-Suppuration, D

See Full Page